FLT4 and cancer: VEGFR-3 tyrosine kinase activity is also inhibited by VEGFR-targeting and less specific tyrosine kinase inhibitors in use or in development for cancer anti-angiogenic or anti-metastatic effects, such as sunitinib, fruquintinib, or cediranib.